Akebia Therapeutics's total assets for Q2 2026 were $349.66M, a decrease of -3.55% from the previous quarter. CH:AX9 total liabilities were $324.64M for the fiscal quarter, a -3.13% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.